Ritter Pharmaceuticals

General Information

Ritter Pharmaceuticals develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health. Our first novel microbiome modulator, RP-G28, an orally administered, high purity galacto-oligosaccharide, is currently under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby effectively adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

Employees: 5
Founded: 2004
Contact Information
Address 1801 Century Park East, #1820, Los Angeles, CA 90067, US
Phone Number (310) 203-1000
Web Address http://www.ritterpharmaceuticals.com
View Prospectus: Ritter Pharmaceuticals
Financial Information
Market Cap $39.4mil
Revenues $0.0 mil (last 12 months)
Net Income $-3.6 mil (last 12 months)
IPO Profile
Symbol RTTR
Exchange NASDAQ
Shares (millions): 4.0
Price range $5.00 - $5.00
Est. $ Volume $20.0 mil
Manager / Joint Managers Aegis Capital Corp/ Chardan Capital Markets
CO-Managers Barrington Research
Expected To Trade: 6/24/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change